Navigation Links
RoosterBio Launches a Closed System Extracellular Vesicle Collection Medium Enabling Scalable and Standardized cGMP Manufacturing

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, today announced the launch of its product RoosterCollect™-EV-CC to enable streamlined and multi-format collection of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC is the only system designed with hMSC-EV product developers in mind. Product developers can now use RoosterBio’s CliniControl™ standardized, scalable and highly productive bioprocess media with high quality cellular starting materials to reduce costs and process times – completing a system for EV production that can readily be implemented in late stage product development and cGMP manufacturing.

In March 2019, RoosterBio brought RoosterCollect™-EV and EV Boost™, “development grade” versions of the product system, successfully to market while outpacing expected sales forecasts. Founder and Chief Product Officer Jon A. Rowley, PhD said, “We launched RoosterCollect™-EV-CC in response to strong market demand for a complete hMSC-EV system. This solution solves the need of the regenerative medicine product developer who requires significant hMSC-derived EV volumes generated from cGMP systems designed with quality, efficiency and scalability in mind.”

Today, a wide range of companies are currently developing EV/exosome-based therapeutic products across diverse applications in the regenerative medicine industry. The EV market is rapidly growing with at least 13,074 scientific articles published, according to and over 140 clinical trials underway, according to hMSCs are reportedly prolific producers of EVs, and are hypothesized to have mechanism of action attributable to EV secretion into the extracellular space. EVs are also being considered as targetable candidate delivery systems for macromolecules like siRNA or miRNA.

RoosterBio’s proprietary, clinically relevant product portfolio manufactured by GenCure was introduced in 2017 under the CliniControl™ brand name. CliniControl™ products radically simplify multiple steps in therapeutic development, allowing product developers to prospectively truncate years of time and millions of dollars from their development timelines.

Rowley added, “This product is a key addition to our cGMP solutions. We’ve proven that our CliniControl™ products are part of the industrialized supply chain of regenerative medicine. We continue to drive unparalleled efficiencies and economies of scale in clinical and commercial hMSC-based product manufacturing.”

About RoosterBio, Inc.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, cost-effective, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and cost savings for customers. RoosterBio's innovative products and collaborative relationships are ushering in a new era of productivity and standardization into the field. Visit

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology
2. RoosterBio Inc. Launches Industry’s First Ready-to-Print Stem Cell Product
3. Designed by RoosterBio Inc.: New Xeno-free Cell Culture Media Product Developed to Accelerate Manufacturing and Commercialization of Adult Stem Cell Products
4. Engineered by RoosterBio Inc.: Universal Bioprocess Bags to Streamline Closed System Stem Cell Production
5. RoosterBio Inc. Unites with Manufacturing Innovation Institutes, Joining Manufacturing USA Network
6. RoosterBio Launches a Xeno-Free Bioreactor Feed to Streamline Cell Expansion & Efficiently Reach Billions of hMSCs
7. Margot Connor, CEO, RoosterBio Inc., Frederick Innovative Technology Center, Inc expected graduate earns “Top 10” Technology Industry Award
8. RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry
9. RoosterBio and GenCure Sign Multiple Agreements to Advance Regenerative Medicine Startups
10. RoosterBio Partners with Senti Biosciences to Rapidly Translate Gene Circuit Cell Therapy into the Clinic
11. Darrow Wealth Management Launches New Website
Post Your Comments:
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in Mexico ... patient's condition, treatment may be offered IV, intrathecal or with a combination. , A ... and the incidence continues to increase as individuals live longer. There is no cure, ...
(Date:7/1/2020)... ... June 29, 2020 , ... The Interlocal ... contracts to its membership, recently named BioFit Engineered Products an Awarded ... to purchase ergonomic seating, cafeteria tables, book trucks and carts at discounted pricing ...
(Date:6/28/2020)... SAN JOSE, Calif. (PRWEB) , ... June 25, ... ... the globe, researchers are racing to develop a vaccine or drug treatment. In ... company Recursion has publicly released the world’s largest imaging dataset portraying ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... facilitate access to unique lab-made bioresearch materials, today announced the availability of the ... Whitt laboratory at University of Tennessee, enables studies of SARS-CoV-2 viral entry and ...
Breaking Biology Technology:
(Date:6/28/2020)... ... June 25, 2020 , ... ... today announced that it has entered into a multi-year contract with Merus ... support their translational and clinical research strategy to discover and develop ground-breaking ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... and Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable energy ... operations in the fight against the COVID-19 pandemic in Zambia. , One of ...
Breaking Biology News(10 mins):